Products
Ceftobiprole was approved in many countries in 2009 as a powder for a concentrate for the preparation of an infusion solution (Zevtera).
Structure and properties
Ceftobiprole (C20H22N8O6S2, Mr = 534.6 g/mol) is present in the drug in the form of the prodrug ceftobiprole medocaril and as a sodium salt. The prodrug is converted to the active drug by esterases in the blood.
Effects
Ceftobiprole (ATC J01DI01) has bactericidal properties against Gram-positive and Gram-negative pathogens. It has broad spectrum and is also effective against resistant pathogens such as MRSA. The effects are based on inhibition of bacterial cell wall synthesis by binding to penicillin binding proteins (PBP).
Indications
For the treatment of bacterial infectious diseases (pneumonia).
Dosage
According to the SmPC. The drug is administered as an intravenous infusion.
Contraindications
- Hypersensitivity to the active substance, components of the drug and related antibiotics (cephalosporins, beta-lactam antibiotics).
Full precautions can be found in the drug label.
Interactions
Ceftobiprole is an inhibitor of OATP1B1 and OATP1B3. Corresponding drug-drug interactions are possible.
Adverse effects
The most common potential adverse effects include nausea, vomiting, diarrhea, hypersensitivity reactions, and taste disturbances.
